IL-19, IL-20, IL-22, IL-24 and IL-26 constitute the IL-20 subfamily of cytokines, a subset of the IL-10 superfamily, which also includes IL-10, IL-28 and IL- 29 (refs. 17-19) . IL-19, IL-20 and IL-24 all signal through the type I IL-20 receptor (IL-20R), a heterodimeric receptor composed of the IL-20R αand β-chains (IL-20RA and IL-20RB, respectively). IL-20 and IL-24 can additionally signal through the type II IL-20R, a heterodimer of IL-20RB and the IL-22 receptor α1 subunit (IL-22RA1). Published work has clarified the structural basis for the specific binding characteristics of these receptors and cytokines 20 . Both of these IL-20RB-containing receptor complexes are expressed mainly on epithelial cells and activate the transcription factor STAT3. That activation drives a program that restores tissue homeostasis by enhancing remodeling, wound healing and the secretion of antimicrobial peptides in a manner similar to the actions of IL-22 (ref. 21) . Distinct from IL-22, which is secreted mainly by lymphocytes, IL-19, IL-20 and IL-24 are produced mainly by myeloid cells and epithelial cells 18 .
IL-19, IL-20 and IL-24 (collectively called 'the IL-20R cytokines' here) have been linked to the pathogenesis of psoriasis. High expression of the IL-20R cytokines has been found in psoriatic tissue samples 22 . In mice and tissue culture systems, overexpression of IL-20 or IL-24 leads to characteristic keratinocyte proliferation, epidermal thickening and induction of psoriasis-associated chemokines and antimicrobial peptides 21, 23, 24 . IL-17A and IL-22, driven by IL-23-mediated activation of STAT3, are also linked to the pathogenesis of psoriasis and have been found to induce expression of members of the IL-20 subfamily 21,25,26 . A r t i c l e s Although the IL-20R cytokines have been associated with psoriasis and other immunopathology, their role in host defense has not been investigated extensively 27, 28 . Given their demonstrated skin-protective actions, we hypothesized that these cytokines would enhance the host response to S. aureus. However, we found that signaling through IL-20RB inhibited the cutaneous inflammatory response and resulted in less production of IL-1β and IL-17A and thereby promoted infection of the skin with S. aureus. Our results identify an antiinflammatory role for signaling via IL-20RB consistent with its known tissue-restorative functions, but those anti-inflammatory characteristics also diminish host defense against infectious agents at epithelial surfaces.
RESULTS

IL-20RB impairs control of cutaneous infection with S. aureus
To determine if the IL-20R cytokines influenced the host response to infection of the skin with S. aureus, we infected wild-type and IL-20RB-deficient (Il20rb −/− ) mice intradermally with 1 × 10 7 colonyforming units of a clinical MRSA isolate (USA300 LAC strain). We then monitored the size of the resultant skin abscesses over 15 d. Il20rb −/− mice developed smaller lesions ( Fig. 1a) with lower bacterial burdens ( Fig. 1b ) than those of their wild-type counterparts. Although IL-22 has documented antimicrobial effects on other mucosal pathogens 29, 30 , Il22 −/− mice did not have altered susceptibility to infection of the skin with MRSA ( Fig. 1c,d) . Histology confirmed that Il20rb −/− mice had smaller abscesses with preserved skin architecture and a greater influx of inflammatory cells relative to those of their wild-type counterparts ( Fig. 1e) , consistent with the critical role of neutrophils in control of cutaneous infection with S. aureus 1 .
As IL-20RB forms one chain of the receptors that bind IL-19, IL-20 and IL-24, we next established the induction of those cytokines during infection of the skin with MRSA. The abundance of transcripts encoding IL-19 and IL-24 increased in infected skin during the initial hours of infection relative to their abundance in uninfected skin and remained high over the course of the infection (Fig. 2a) . In contrast, expression of IL-20 was not induced during infection ( Fig. 2a) . Expression of both IL-20RA and IL-20RB, which combine to form a heterodimeric receptor for IL-19, IL-20 and IL-24, was induced within 2 h of infection, with a subsequent return to baseline by day 3 (Fig. 2b) . Expression of IL-22RA1, which forms a heterodimer with IL-20RB to generate a receptor for IL-20 and IL-24 but not IL-19, had a similar pattern of induction during infection ( Fig. 2b) .
To confirm data obtained with our Il20rb −/− mouse suggesting that signaling via IL-20R promoted infection of the skin with S. aureus, we injected wild-type mice with MRSA resuspended in recombinant IL-20R cytokines. Consistent with our findings obtained with Il20rb −/− mice, injection of recombinant mouse IL-19 led to the development of larger lesions ( Fig. 2c ) and greater bacterial burdens ( Fig. 2d ) than did injection of PBS. Mice produced IL-24 but not IL-20 in response to infection with MRSA ( Fig. 2a) . However, because those two cytokines induce a similar epithelial gene signature 21 and similarly use both types of IL-20R, we injected mice with recombinant mouse IL-20 as a surrogate for IL-24, which is not available commercially. Injection of recombinant IL-20 had effects on infection with MRSA similar to those achieved by injection of recombinant mouse IL-19 ( Supplementary Fig. 1 ), consistent with use of the type I IL-20R by both IL-19 and IL-20. Although we cannot rule out the possibility of unique effects of IL-24, the results of treatment with recombinant IL-20 also suggested that signaling via the type II IL-20R did not alter the observed susceptibility conferred by signaling via the type I IL-20R. Analysis of infected skin showed an inflammatory infiltrate composed mainly of neutrophils (Ly6C + Ly6G + cells; Fig. 2e ). Treatment with recombinant IL-19 did not substantially affect the relative composition of cells in infected tissue ( Fig. 2e ) but resulted in a much lower absolute number of cells ( Fig. 2f ). Together these results showed that the IL-20R cytokines were induced by infection of the skin with S. aureus and impaired the inflammatory response required for optimal host defense.
IL-20R cytokines inhibit the IL-17A response to S. aureus Consistent with published literature indicating a critical role for γδ T cell-derived IL-17A in the recruitment of neutrophils and protection against cutaneous infection with S. aureus 14 , we found a transient increase in the abundance of transcripts encoding IL-17A in infected skin early after infection ( Fig. 3a) . IL-17A expression then increased substantially by 3 d after infection and remained high through at least day 14 ( Fig. 3a) . Expression of DEFB4, an anti-staphylococcal peptide induced by IL-17A 31 , followed the observed early and late kinetics of IL-17A expression ( Fig. 3b) . Expression of IL-17F and IL-22, cytokines commonly associated A r t i c l e s with IL-17A responses, appeared only later during the course of infection ( Fig. 3b) .
We hypothesized that alterations in the production of IL-17A contributed to the enhanced susceptibility to S. aureus conferred by IL-20R signaling. Consistent with that, we found that treatment with recombinant IL-19 or IL-20 concurrent with infection significantly inhibited IL-17A expression in skin 2 h after infection, and this inhibition persisted at 6 d ( Fig. 3c) . Furthermore, Il20rb −/− mice showed a trend toward higher IL-17A expression 2 h after infection that became significant by 6 d (Fig. 3c) . Expression of IL-17F, IL-22 and interferon-γ was not altered by stimulation of or deficiency in IL-20R ( Supplementary Fig. 2a ). Expression of the antimicrobial products npg DEFB4 and S100A9 was consistent with their known induction by IL-17A, but induction of S100A8 expression by treatment with recombinant IL-19 suggested alternative regulation of the gene encoding S100A8 (Supplementary Fig. 2b ). Flow cytometry of skin cells early and late after infection confirmed the induction of IL-17A + cells ( Fig. 3d-g) . At 4 d after infection, infected tissue treated with recombinant IL-19 had fewer IL-17A + cells than did infected tissue not treated with recombinant IL-19 ( Fig. 3f-g) . Consistent with published reports 14 , the IL-17A + cells induced in infected skin were predominantly γδ T cells ( Supplementary Fig. 3a,b) . Those γδ T cells had intermediate expression of the γδ T cell antigen receptor (γδ TCR int ; Supplementary Fig. 3a,b) , in accordance with the reported ability of dermal γδ T cells (γδ TCR int ) rather than epidermal γδ T cells (γδ TCR hi ) to secrete IL-17A 32 . To determine if a greater abundance of IL-17A explained the protection conferred by Il20rb deficiency, we injected neutralizing antibody to IL-17A (anti-IL-17A) into the inoculum at the time of infection with MRSA. This abrogated the difference between Il20rb −/− mice treated with control antibody and wild-type mice in their lesion size ( Fig. 3h ) and bacterial burden ( Fig. 3i) , which confirmed the IL-17A-dependent protection in Il20rb −/− mice. However, administration of anti-IL-17A led to more severe infection in wild-type mice than in Il20rb −/− mice ( Fig. 3h,i) , which indicated the presence of additional IL-17A-independent protective mechanisms in the Il20rb −/− mice. Together these experiments showed that suppression of IL-17A by the IL-20R cytokines contributed to their negative effect on control of infection of the skin with S. aureus.
IL-20R cytokines inhibit pro-IL-1b mRNA expression
As the type I and type II IL-20R complexes do not seem to be expressed on lymphocytes 19, 33 , we hypothesized that the decrease in IL-17A noted after exposure to the IL-20R cytokines reflected an effect on the IL-17A-inducing cytokines produced by IL-20RB-expressing keratinocytes and myeloid cells 19 . Whereas IL-6 is critical for the induction of IL-17A in CD4 + T cells 34 , IL-1β and IL-23 are major inducers of IL-17A in γδ T cells 35 . IL-1β can further feed back onto keratinocytes to enhance IL-23 expression 36 . Expression of pro-IL-1β, IL-6, and IL-23 was induced within hours of infection of the skin with MRSA ( Fig. 4a) . Il20rb −/− mice had higher expression of pro-IL-1β mRNA 2 h after infection than did their wild-type counterparts (Fig. 4b) .
Treatment of wild-type mice with recombinant IL-19 or IL-20 suppressed the MRSA-induced expression of pro-IL-1β, IL-6 and IL-23 at that time point ( Fig. 4b) . By the peak of infection on day 6, signaling via IL-20R continued to have similar effects on pro-IL-1β expression, and the effects on IL-23 became more pronounced (Fig. 4c) .
The broader and more pronounced effect on cytokine expression seen after treatment with recombinant IL-20R cytokines than with IL-20RB deficiency may have reflected compensatory mechanisms in the Il20rb −/− mice or a difference between the physiological amounts of these cytokines in vivo and our selected treatment doses. Overall, suppression of pro-IL-1β expression seemed to be the earliest and most consistent effect of IL-20R signaling on these IL-17A-inducing cytokines. Consistent with the reported dependence of IL-20R signaling on STAT3, transgenic mice with a mutation in Stat3 (∆V463) that models the STAT3 dysfunction in human Job's syndrome did not respond to recombinant mouse IL-19, as assessed by lesion size, bacterial burden and IL-1β expression after infection with MRSA ( Fig. 4d-f) .
The ability of IL-1β to positively regulate its own transcription 37 suggests that the observed early changes in pro-IL-1β mRNA may have reflected direct effects of the IL-20R cytokines on inflammasomemediated post-translational processing of pro-IL-1β into IL-1β. However, exposure to the IL-20R cytokines inhibited the induction of transcripts encoding pro-IL-1β in a mouse keratinocyte cell line (PAM 2-12) within 30 min of exposure to S. aureus (bioparticles of the Wood 46 strain; Fig. 5a ). We did not detect differences between untreated and cytokine-treated cells in their production of IL-1β protein until 3 h after exposure to S. aureus, and these differences became more pronounced by 24 h after exposure to S. aureus (Fig. 5b-d) , which indicated that the IL-20R cytokines directly altered the abundance of pro-IL-1β mRNA before any changes in post-translational processing affected the amount of mature IL-1β protein. To detect mature IL-1β protein, which is indistinguishable from pro-IL-1β by the antibodies available for enzyme-linked immunosorbent assay and flow cytometry, we used immunoblot analysis and confirmed a greater abundance of both pro-IL-1β and cleaved IL-1β in Il20rb −/− primary keratinocyte cultures than in their wildtype counterparts after 24 h of exposure to MRSA (Fig. 5e) .
The data reported above indicated that the effect of the IL-20R cytokines on pro-IL-1β was too rapid to be mediated by transcriptional 
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A r t i c l e s regulation of molecules that control pro-IL-1β expression. Indeed, the expression of molecules that regulate pro-IL-1β expression, such as Toll-like receptor 2 (TLR2), IL-1R antagonist (IL-1Ra), stimulatory IL-1R1 or inhibitory IL-1R2, was not modulated during infection with MRSA by loss or gain of IL-20R signaling in a manner that fully explained the observed effects on IL-1β expression ( Fig. 5f) .
Transcriptional control of pro-IL-1β is also known to involve the transcription factor C/EBP-β, whose activity can be rapidly regulated by post-translational modification and which influences the transcription of genes encoding many inflammation-associated cytokines 38, 39 . MRSA-stimulated keratinocytes from Il20rb −/− mice seemed to have more of the active isoform of C/EBP-β (LAP) than did their wildtype counterparts (densitometry values above background: 2.09 ± 0.2 (Il20rb −/− ) versus 0.99 ± 0.3 (wild-type); P = 0.03 (two-tailed unpaired A r t i c l e s t-test), whereas densitometry values for actin were not significantly different for those mice; Fig. 5g ). After immunoprecipitation of proteins containing the inhibitory small ubiquitin-related modifier SUMO, we detected less C/EBP-β in Il20rb −/− keratinocytes than in their wild-type counterparts (densitometry (as above): 41.36 ± 0.6 versus 45.47 ± 1; P = 0.02 (two-tailed unpaired t-test); Fig. 5g ), which indicated diminished capacity, in the presence of IL-20R signaling, for C/EBP-β to induce the transcription of genes encoding proinflammatory mediators such as IL-1β. Consistent with that, immunoprecipitation of C/EBP-β showed that treatment of keratinocytes with the IL-20R cytokine inhibited MRSA-induced binding of DNA by C/EBP-β at the locus encoding IL-1β (Fig. 5h) . In sum, these results suggested that the IL-20R cytokines inhibited transcription of the gene encoding pro-IL-1β by mechanisms that involved STAT3 and the post-translational inactivation of C/EBP-β.
IL-1b 'rescues' IL-20R-induced susceptibility to S. aureus
The studies reported above of keratinocyte cell lines and primary keratinocytes were consistent with a direct effect of the IL-20R cytokines on keratinocytes. Treatment with the IL-20R cytokines also inhibited induction of the expression of IL-1β protein in vivo in keratinocytes at the MRSA abscess site on day 3 of infection (Fig. 6a) . Administration of recombinant mouse IL-1β at the time of MRSA inoculation overcame the effects of recombinant mouse IL-19 on lesion size (Fig. 6b) , bacterial load ( Fig. 6c) and expression of IL-17A mRNA (Fig. 6d) . Mice deficient in IL-1R1, but not those deficient in IL-17A, did not upregulate expression of IL-19 or IL-24 in response to infection with MRSA ( Fig. 6e) , which suggested that the IL-20R cytokines acted as an inhibitory feedback mechanism triggered by IL-1β. Together these results suggested that signaling via IL-20R resulted in more inactivation of C/EBP-β by SUMO, which led to the observed diminished transcription of the gene encoding pro-IL-1β and subsequent failure to activate downstream inflammatory events, including induction of IL-17A, that have been shown to be critical for the recruitment of neutrophils needed for control of S. aureus.
IL-20RB blockade holds therapeutic potential for humans
To assess the potential therapeutic effect of blocking IL-20R signaling during infection with S. aureus, we included anti-IL-20RB in the MRSA inoculum at the time of infection. That single dose of antibody resulted in significantly smaller lesions and a trend toward a lower bacterial burden (Fig. 7a,b) , which confirmed the phenotypes of the Il20rb −/− mice and mice treated with recombinant cytokines and emphasized the therapeutic potential of optimized targeting of the IL-20R cytokine pathway. Anti-IL-20RB most prominently augmented the induction of pro-IL-1β mRNA (Fig. 7c) , consistent with the effects of the IL-20R cytokines reported above. Similar to its effects in vivo, anti-IL-20RB also enhanced IL-1β production when applied directly to PAM2-12 mouse keratinocytes (Fig. 7d) . To determine if the effects of the IL-20R cytokines might be relevant to humans, we derived primary keratinocyte cultures from samples of human foreskin. Within 1 h of exposure to MRSA, human keratinocytes upregulated expression of all of the IL-20R cytokines (Fig. 7e) . In contrast to mouse cells, human keratinocytes had higher expression of IL-20 than of IL-19 or IL-24. That species-specific induction pattern was reflected in the ability of recombinant human IL-20, but not recombinant human IL-19, to mirror the effects of its mouse counterpart and inhibit induction of the expression of IL-1β mRNA and protein by MRSA in primary human keratinocytes ( Fig. 7f,g) . These data suggested that blockade of IL-20R may hold therapeutic potential for patients with recurrent or severe infection of the skin with S. aureus.
DISCUSSION
Our data have identified the ability of the IL-20R cytokines to promote infection of the skin with S. aureus. To our knowledge, this is the first description of a role for these cytokines during infection. We have shown that this ability to promote infection was due to suppression of antimicrobial inflammatory pathways, which characterizes the antiinflammatory properties of these cytokines during host defense.
Anti-inflammatory properties are consistent with the tissuerestorative functions ascribed to the IL-20R cytokines and befit 
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A r t i c l e s their relatedness to the prototypical anti-inflammatory cytokine IL-10. However, an immunosuppressive role for these cytokines may seem paradoxical, given the ability of overexpression of the IL-20R cytokines to drive psoriasis-like disease in mice 23, 24 . This paradox can perhaps be resolved by distinguishing two distinct characteristics of psoriasis: epithelial proliferation (consistent with known actions of these cytokines) and inflammation (which may be driven by other pathways). The dependence of the induction of IL-20R cytokine expression on IL-1R signaling during infection with S. aureus in our studies, as well as published reports documenting such induction by inflammatory mediators such as IL-1β and IL-17A 40, 41 , suggest that the anti-inflammatory activities of these cytokines may serve as a mechanism for feedback inhibition. Indeed, published work has suggested an immunoregulatory role for IL-19 in colitis 42, 43 , and we have now identified an inhibitory function for these cytokines on IL-1β-driven inflammation during infection. It remains unclear if detection of the IL-20R cytokines in autoimmune diseases such as rheumatoid arthritis [44] [45] [46] reflects an etiological role or an ineffective feedback pathway triggered by inflammation. In any case, our results suggest that these cytokines have immunosuppressive properties that may contribute to susceptibility to infection in a variety of contexts. Our findings have defined the sequence of events triggered by IL-20RB signaling that promote infection of the skin with S. aureus. The induction of IL-1β expression after recognition of S. aureus by TLR2, Nod2 and other pattern-recognition receptors is critical for triggering the inflammatory response, including the IL-17A-dependent recruitment of neutrophils required for clearance of infection 1 . We found that signaling via IL-20RB acted in a STAT3-dependent manner to interfere with that early induction of the expression of IL-1β and related inflammatory cytokines and rapidly increased post-translational sumoylation of C/EBP-β that led to less binding of C/EBP-β to the promoter of the gene encoding pro-IL-1β. The central role for C/EBP-β in transcribing genes encoding many inflammatory cytokines 38, 39 suggests that this mechanism is a major contributor to the anti-inflammatory consequences of signaling via IL-20RB.
Expression of IL-19 and IL-24, but not of IL-20, was induced in mouse skin by infection with MRSA, a pattern similar to that described for such induction by inflammatory cytokines such as IL-23 (ref. 47 ). The differences in the regulation of these related cytokines remain to be elucidated, but given their known expression patterns, it is likely that during infection, their expression is induced in keratinocytes and resident cells of the innate immune system. We found that the cytokines IL-19, IL-24 and IL-20 acted on keratinocytes, which are known to express the type I and type II IL-20R, to suppress IL-1β expression. There are probably similar effects on other IL-20R-expressing resident cell populations, including myeloid cells. We were unable to assess the specific effects of IL-24, which signals through both the type I and type II IL-20R, because of commercial unavailability of the recombinant cytokine. However, the similar receptor use of IL-20 and IL-24 allowed us to use recombinant mouse IL-20 to assess the contribution of signaling via the type II IL-20R, which is not engaged by IL-19. Treatment with either recombinant IL-19 or recombinant IL-20 affected infected mice and keratinocytes similarly. This suggested that the observed effects were mediated mainly by the type I receptor complex, although the unique effects of IL-20, relative to those of IL-19, on the expression of TLR2 and IL-1R1 would suggest that the type II IL-20R may additionally contribute to the phenotype attributable to IL-20RB observed during infection with MRSA. IL-20 was the IL-20R cytokine whose expression was most induced by MRSA in human keratinocytes, which suggests further species differences in the regulation of individual members of this family of cytokines.
The IL-20R cytokines are closely related to IL-22, and published studies of reconstituted human epidermis have shown similar induction of the expression of antimicrobial peptides and other factors 21 . However, Il20rb −/− mice do not have altered susceptibility to colitis induced by Citrobacter rodentium, in which IL-22 serves a protective role 29 . In our studies, expression of IL-22, unlike that of the IL-20R cytokines, was not induced until relatively late in the course of infection with S. aureus; this was a possible contributing factor to the lack of influence of IL-22 on the overall control of infection in this model. The IL-20R cytokines generally have modest to negative effects, relative to those of IL-22, on the induction of proteins that attract neutrophils in reconstituted human epidermis 21 , which suggests that the suppressive effects on IL-1β and IL-17A identified in our studies predominated over the inhibitory effect of signaling via IL-20RB on the recruitment of neutrophils. Such gene-expression differences in response to IL-22 and the individual IL-20R cytokines 21 suggest unique aspects of signaling by each of these cytokines despite their common activation of STAT3, a finding consistent with the inability of IL-6, which also signals through STAT3, to suppress MRSA-induced IL-1β production in mouse keratinocytes (data not shown). Thus, although IL-22 and the IL-20R cytokines may share some properties related to the activation of STAT3, epithelial proliferation and wound healing, they seem to have distinct immunological functions. IL-22 enhances direct antimicrobial activity during certain mucosal infections, whereas the IL-20R cytokines suppress host defense mechanisms by eliciting anti-inflammatory pathways.
Our identification of the immunosuppressive effects of the IL-20R cytokines in the context of infection of the skin with S. aureus has demonstrated their potential to act as anti-inflammatory mediators. This activity may contribute to their effects on epithelial proliferation and wound healing. However, it also identifies them as potentially important inhibitors of inflammatory pathways involving IL-1β, IL-23 and IL-17A, which suggests that augmentation of IL-20R signaling may be a potential therapy for inflammatory and autoimmune diseases. Such augmentation, however, may result in a predisposition to susceptibility to infection. This raises the possibility that intrinsic susceptibility to infection with S. aureus, as in atopic dermatitis and some immunodeficiencies, may reflect overly exuberant signaling via IL-20R that could be modulated for therapeutic benefit.
METHODS
Methods and any associated references are available in the online version of the paper.
